#### FULL -LENGTH PAPER

# **One-pot diastreoselective synthesis of highly functionalized cyclohexenones: 2-oxo-N,4,6-triarylcyclohex-3-enecarboxamides**

**Mir Rasul Mousavi · Malek Taher Maghsoodlou · Sayyed Mostafa Habibi-Khorassani**

Received: 27 May 2014 / Accepted: 13 July 2014 / Published online: 6 August 2014 © Springer International Publishing Switzerland 2014

**Abstract** A series of 2-oxo-N,4,6-triarylcyclohex-3 enecarboxamides were synthesized by condensing acetophenone and aromatic aldehydes with acetoacetanilide in ethanol in the presence of 2-hydroxyethylammonium acetate (2- HEAA) as a basic ionic liquid at ambient conditions. This process is simple, efficient and environmentally benign and proceeds in high yield, short reaction times and there is no need for column chromatography purification.

**Keywords** Highly functionalized cyclohexenone · 2-Oxo-N,4,6-triarylcyclohex-3-enecarboxamide · Ionic liquid · One-pot · 2-Hydroxyethylammonium acetate

#### **Introduction**

Commonly,  $\alpha$ ,  $\beta$ -Enone is known as chalcone. Chalcones own an  $\alpha$ , β-unsaturated grouping with two aromatic rings in the molecules. A highly electrophilic three-carbon  $\alpha, \beta$ unsaturated carbonyl system has interconnected the rings (Fig. [1\)](#page-1-0) [\[1](#page-6-0)[–4\]](#page-6-1). Chalcones are very reactive compounds and increase their reactivity due to a keto-ethylinic type (–CO–CH=CH–) conjugated double bond system present in the structure [\[5](#page-6-2)[–7\]](#page-6-3). Chalcones have occupied a unique place in medicinal and biological chemistry. Chalcones and derivatives comprise a significant class of compounds possessing diverse biological and pharmacological properties includ-

**Electronic supplementary material** The online version of this article (doi[:10.1007/s11030-014-9541-7\)](http://dx.doi.org/10.1007/s11030-014-9541-7) contains supplementary material, which is available to authorized users.

ing anti-bacterial  $[4,8,9]$  $[4,8,9]$  $[4,8,9]$  $[4,8,9]$ , anticonvulsant  $[10]$ , anti-cancer [\[11](#page-6-7)], anti-fungal [\[12,](#page-6-8)[13\]](#page-6-9), antiprotozoal [\[14](#page-6-10)], antimalarial  $[1,2,15]$  $[1,2,15]$  $[1,2,15]$  $[1,2,15]$ , larvicidal  $[16]$  $[16]$ , antifilarial  $[17]$ , anti-inflammatory [\[18](#page-6-15)], antioxidant [\[19,](#page-6-16)[20\]](#page-6-17), and antimicrobial [\[21](#page-6-18)]. Also, they have been identified as inhibitors of enzymes, specifically mammalian alpha-amylase [\[3](#page-6-19)[,22](#page-7-0)], monoamine oxidase  $(MAO)$  [\[23](#page-7-1)], and cyclo-oxygenase  $(COX)[24]$  $(COX)[24]$  $(COX)[24]$ . The conjugate addition of a stabilized carbanion to  $\alpha$ ,  $\beta$ -unsaturated carbonyl compounds is one of the fundamental C–C bondforming reactions in organic synthesis [\[25](#page-7-3)[–27](#page-7-4)]. Therefore, an important feature of chalcones is their ability to act as activated unsaturated systems in conjugated additions of carbanions in the presence of suitable basic catalysts [\[28,](#page-7-5)[29\]](#page-7-6). For example, the Michael addition of ethylacetoacetate to chalcone yields 4,6-diaryl-2-oxo-cyclohex-3-ene-1-carboxylate derivatives which are efficient synthons for building spiranic compounds [\[30\]](#page-7-7), and are also important intermediates in the synthesis of joined heterocycles, such as benzopyrazoles and benzisoxazoles [\[31\]](#page-7-8), benzoselenadiazoles and benzothiadiazoles [\[32](#page-7-9)], 2H-indazoles [\[33](#page-7-10)], and carbazole derivatives [\[34](#page-7-11)]. Cyclohexenone derivatives are well-known lead molecules for the treatment of inflammation and autoimmune diseases [\[35](#page-7-12),[36\]](#page-7-13). Also, cyclohexenone and inazole derivatives exhibit a variety of pharmacological properties, such as antitumor [\[37\]](#page-7-14), tyrosine kinases inhibitor [\[38](#page-7-15)], antipyretic [\[39](#page-7-16)], antiasthametic [\[40\]](#page-7-17), antiviral [\[41\]](#page-7-18), anti-bacterial, anti-fungal, anti-cancer, and anti-tubercular activity [\[42\]](#page-7-19). Because of the importance of cyclohexenone derivatives from a pharmaceutical and biological point of view, there is still a need to develop efficient, mild, and environmentally benign protocols for the synthesis of these compounds. Herein we present an eco-friendly procedure for the synthesis simple and effi cient and characterization of a novel series cyclohexenone derivatives called 2-oxo-N,4,6-triarylcyclohex-3-enecarboxamides via a one-pot three-component reaction using ace-

M. R. Mousavi · M. T. Maghsoodlou (B) · S. M. Habibi-Khorassani Department of Chemistry, Faculty of Science, University of Sistan and Baluchestan, P. O. Box 98135-674, Zahedan, Iran e-mail: mt\_maghsoodlou@yahoo.com

#### <span id="page-1-0"></span>Fig. 1 Structure of chalcone



<span id="page-1-1"></span>**Table 1** Condensation reaction of acetophenone, 4-methoxy benzaldehyde, and acetoacetanilide in the presence of different loadings of various catalysts at ambient conditions<sup>a</sup>

tophenone 1, aromatic aldehydes 2, and 3-oxo-N-phenylbutanamide (acetoacetanilide) **3** in the presence of 2-hydroxyethylammonium acetate as a ionic liquid in ethanol at room temperature (Scheme 1).

#### **Results and discussion**

We first examined the reaction of 4-methoxy benzaldehyde and acetophenone with acetoacetanilide using 15 mol% of different catalysts. In the initial search for an efficient catalyst, four different ionic liquids were screened in our model reaction. The reaction did not progress even after 48 h in the absence of catalyst. As shown in Table [1,](#page-1-1) the reaction was performed in the presence of diethylammonium hydrogen sulfate (DEAS), triethylammonium hydrogen sulfate (TEAS), and triethylammonium dihydrogen phosphate (TEAP), the desired product was obtained in low yields along with undesired by-products. However, after optimizing the catalyst amount, we found that 20 mol% 2-hydroxyethylammonium acetate (2-HEAA) gave desired product in high yields. Increasing the catalyst loading did not improve product yields (entries, 8 and 9). Also, we found that when the reactions were run under solvent-free and under optimized conditions, the reaction did not lead to the desired product (Table [1,](#page-1-1) entry 10) which could be due to the lack of effective interaction between reactants and the catalyst in the absence of solvent.

During the course of screening a variety of reaction conditions such as solvent, reaction temperature, and the amount of the catalyst, we found that the use of ethanol as a solvent was essential for the efficient conversion of raw materials to (1R,6S)/(1S,6R)-6-(4-methoxyphenyl)-2-oxo-N,4-diphenylcyclohex-3-enecarboxamide **4d**. It is remarkable that, ethanol is a green solvent. The structure of (1R,6S)/(1S,6R)-6-(4-methoxyphenyl)-2-oxo-N,4-diphenylcyclohex-3-enecarboxamide **4d** was confirmed by spectral techniques, such as like  ${}^{1}$ H-NMR,  ${}^{13}$ C-NMR, elemental, and mass spectral analysis. The products obtained in this work are chiral compounds. They have two chiral centers on **C-1** and **C-6**, with protons in *anti*-configuration. Also, the protons

 $\rm CH_{3}$ O CHO **1 2 3 4d** O O N H IL EtOH, rt N H O **O** OCH<sub>3</sub>  $CH<sub>3</sub>$ Entry Catalyst Solvent Catalyst (mol%) Time (h) Yield (%)<sup>*a*</sup>



<sup>a</sup> All the reactions were carried out using, acetophenone 1 mmol, 4-methoxy benzaldehyde 1 mmol and acetoacetanilide 1 mmol with varying amounts of catalysts in EtOH (5 mL) at room temperature <sup>b</sup> Yield refers to the pure isolated products



**Fig. 2** Stereogenic centers on the structure of 2-oxo-N,4,6 triarylcyclohex-3-enecarboxamides

<span id="page-1-2"></span>on **C-5** are diastereotopic. This reaction leads to the creation of two stereogenic centers (Fig. [2\)](#page-1-2).

To explore the scope of our methodology, we extended this reaction to various aromatic aldehydes in the presence of electron-withdrawing  $(NO<sub>2</sub>, Cl, CN, and Br)$  and electronreleasing (OMe) substituents, both of which gave the desired



<span id="page-2-0"></span>**Table 2** Synthesis of 2-oxo-N,4,6-triarylcyclohex-3-enecarboxamides in the presence of ethanol ammonium acetate

Entry	Product	R	Time(h)	Yield $(\%)^a$	M.p. (°C)
1	4a	$2-Br$	15	99	$220 - 222$
2	4 <sub>b</sub>	$3-NO2$	20	96	$200 - 202$
3	4c	$2-C1$	40	97	$224 - 226$
$\overline{4}$	4d	$4-OMe$	45	96	$217 - 219$
5	4e	$4-NO2$	18	94	$202 - 204$
6	4f	$2.6$ -Cl <sub>2</sub>	15	95	188-190
7	4 <sub>g</sub>	$4-CN$	25	99	$224 - 226$
8	4 <sub>h</sub>	$3-C1$	30	95	187-189
9	4i	3-pyridin-	45	92	195-197
10	4j	4-pyridin-	10	97	$202 - 204$
11	4k	$2,3-(OME)$	35	90	196-198

Bold represents the best conditions for the reaction during the course of the screening of different catalysts

*<sup>a</sup>* Yields refer to the pure isolated products

product. The results are shown in Table [2.](#page-2-0) These results show that the functional groups did not play any significant role in the reactivity of the substrate.

The cyclo-condensation of acetoacetanilide with chalcones leads to the generation of two chiral centers at **C-1** and **C-6** in the structure of cyclohexenones. The products were fully characterized by melting points, elemental analyses, IR,  ${}^{1}$ H and  ${}^{13}$ C NMR, and mass spectra. For example, the IR spectra of **4g** revealed a sharp absorption band at 3308 cm−<sup>1</sup> associated to NH, while a strong stretching band at 2230 cm<sup>-1</sup> was attributed to  $C \equiv N$ . Furthermore, two sharp strong absorption bands were noticed at approximately 1672 and 1656 cm<sup>-1</sup> and were assigned to the carbonyl groups. The  ${}^{1}$ H and  ${}^{13}$ C NMR, and mass spectra substantiated the results of the IR analysis. The mass spectrum of  $4g$  recorded a molecular ion signal  $(M^+)$  at  $m/z = 392$ , which is consistent with the proposed structure. The 1H NMR spectrum of compound **4g**, exhibited two doublets of doublets at 3.07 ppm ( $J = 18.0, 4.0$  Hz) and 3.18 ppm  $(J = 17.6, 10.4 \text{ Hz})$  for methylene protons of cyclohexenone ring (H-5, H'-5) respectively. One of the methine protons of cyclohexenone ring (H-6) was observed as a triplet of doublet (td) at  $\delta$  3.95 ppm ( $J = 13.2$ , 4.8 Hz) and another methine proton (H-1) appeared as a doublet at  $\delta$  4.02 ppm  $(J = 13.2$  Hz). The vinyl proton (H-3) was observed as a doublet at 6.60 ppm ( $J = 1.6$  Hz). The aromatic protons were recorded as doublets and triplets at  $\delta$  7.01–7.80 ppm. The NH proton was observed at  $\delta$  10.10 ppm, indicating an intramolecular hydrogen bond interaction with the vicinal carbonyl group on cyclohexenone ring. The  ${}^{13}$ C-NMR spectrum of compound **4g** showed 20 distinct signals consistent with the cyclohexenone structure. According to the structure of **4g**, 25 carbon signals should be present in the 13C NMR spectrum. However, due to the same carbons of (**C-3**, **C-5**)

and (**C-2**, **C- 6**) in the aromatic rings in the structure of **4g**, on the 13C NMR spectrum one signal is observed for each of the pairs. In the  $^{13}$ C NMR spectrum of this compound, the **C-6** carbon was observed at δ 35.1 ppm and **C-5** at δ 43.4 ppm. The **C-1**, **C-3**, and **C-4** carbon signals were observed at  $\delta$  59.3, 126.9, and 159.2 ppm, respectively. The C  $\equiv$  N and aromatic carbons were found at  $\delta$  110.2-148.3 ppm. In addition, the carbon of carbonyl of amide group was shown at  $\delta$  167.4 ppm. And, the carbon of carbonyl of conjugated double bond C=C system (**C-2**) was observed at 195.3 ppm.

A part of the  ${}^{1}H$  NMR spectrum of 4b is shown in Fig. [3.](#page-3-0) In this figure, four protons of cyclohexenone, H-5, H'-5, H-1, and H-6 were characterized and assigned.

A reasonable pathway for the synthesis of highly substituted cyclohexenone derivatives is given in Scheme 2. The Claisen-Schmidt condensation method for the synthesis of chalcones is very attractive, since it specifically generates the trans (E)-isomer [\[43](#page-7-20)[–45](#page-7-21)]. Hence, the reaction of acetophenone **1** with different aryl aldehydes **2** in the presence of catalytic amount of 20 mol% 2-hydroxyethylammonium acetate afforded the desired chalcone **5**. Subsequently, Michel addition of chalcone with acetoacetanilide **3** in the presence of IL followed by internal Claisen condensation gives 2-oxo-N,4,6-triarylcyclohex-3-enecarboxamides **4**.

In conclusion, we have disclosed an extremely facile and environmentally benign synthesis of a series of 2-oxo-N,4,6 triarylcyclohex-3-enecarboxamides via reaction of acetophenone and different aromatic aldehydes with acetoacetanilide under room temperature with ethanol as green solvent by the use of a catalytic amount of 2-hydroxyethylammonium acetate (2-HEAA). This work not only offers substantial improvements in reaction rates and yields, but also avoids the use of hazardous catalysts or solvents. Moreover, the mild reaction conditions, high yields, easy work-up, and clean reaction profiles are some of the advantages of this procedure. Therefore, this protocol is eco-friendly.

It is worth noting that literature procedures generally point to the synthesis of cyclohexenone derivatives in two steps. Such as in the first step chalcone is synthesized from the reaction of aldehyde and acetophenone. After isolation, purification and characterization, in the second step chalcone would react in new conditions for preparing cyclohexenone derivatives. But in the present work, synthesis of novel cyclohexenones (2-oxo-N,4,6-triarylcyclohex-3 enecarboxamides) is discussed in a one-pot three-component reaction.

#### **Experimental**

#### General

Melting point and IR spectra of all compounds were obtained on an Electrothermal 9100 apparatus and a JASCO FT/IR- derivatives

<span id="page-3-0"></span>

460 plus spectrometer, respectively.  ${}^{1}$ H and  ${}^{13}$ C NMR spectra of compounds were recorded on a Bruker DRX-400 Avance instrument using DMSO or CDCl<sub>3</sub> as the solvent and TMS as an internal standard at 400 and 100 MHz, respectively. Elemental analyses for C, H, and N for the new compounds were performed using a Heraeus CHN-O-Rapid analyzer. The mass spectra for the new compounds were recorded on an Agilent Technology (HP) mass spectrometer, operating at an ionization potential of 70 eV. All reagents were purchased from Merck (Darmastadt, Germany), Acros (Geel, Belgium) and Fluka (Buchs, Switzerland), and use without further purification.

Typical procedure for the preparation of 2-hydroxyethylammonium acetate (2-HEAA)

As reported in the literature [\[46](#page-7-22)[,47](#page-7-23)], for the synthesis of ionic liquid (2-HEAA) a solution of acetic acid (50 mmol, 3.00 g) in EtOH (1.5 mL) was added dropwise to a stirring solution of 2-aminoethanol (50 mmol, 3.05 g) in EtOH (1.5 mL) at room temperature within 1 h. The resulting solution was stirred at room temperature for another 20 h. Ethanol was removed in vacuo and the residual was dried in vacuo at 50 ◦C for 48 h to give 2-hydroxyethylammonium acetate (2-HEAA) as a light yellow, viscous liquid.

General procedure for the preparation 2-oxo-N,4,6 triarylcyclohex-3-enecarboxamide derivatives

To a solution of acetophenone (1 mmol), aromatic aldehyde (1 mmol), and acetoacetanilide (1 mmol) was added 2-HEAA 20 mol%. The resulting mixture was stirred for the appropriate time (Table [2\)](#page-2-0) at room temperature. After completion of the reaction, as indicated by TLC (ethyl acetate/n-hexane, 1:3), a thick precipitate was obtained. The solid was filtered, washed with ethanol, and crystallized from ethanol to give pure product. The pure products were characterized by conventional spectroscopic methods. Physical and spectral data for the synthesized compounds are represented below:

### *6-(2-bromophenyl)-2-oxo-N,4-diphenylcyclohex-3 enecarboxamide (4a)*

White solid, yield: (99 %); mp 220–222 ◦C. IR (KBr)  $(v_{\text{max}}/\text{cm}^{-1})$ : 3411, 1676, 1629, 1601, 1557, 1445, 1370, 1248, 1181, 757, 693. 1H NMR (400 MHz, DMSO): 3.01 (s, 2H, H-5), 4.20 (d, *J* = 13.2 Hz, 1H, H-1), 4.26 (dd, *J*= 9.6, 5.2 Hz, 1H, H-6), 6.63 (s, 1H, H-3), 7.01 (t, *J* = 7.2 Hz, 1H, Ar-H), 7.17 (t, *J* = 7.2 Hz, 1H, Ar-H), 7.24 (t, *J* = 7.6 Hz, 2H, Ar-H), 7.40 (t, *J* = 7.6 Hz, 1H, Ar-H), 7.46 (d, *J* = 6.0 Hz, 5H, Ar-H), 7.62 (dd, *J* = 11.6, 8.0 Hz, 2H, Ar-H), 7.72 (d,  $J = 7.6$  Hz, 2H, Ar-H), 10.21 (s, 1H, NH). <sup>13</sup>C NMR (100 MHz, DMSO): δ 34.8, 42.2, 58.7, 119.5, 123.8, 123.9, 124.5, 126.8, 128.2, 128.5, 129.1, 129.3, 129.4, 131.0, 133.4, 137.6, 139.1, 141.1, 158.7, 167.3, 195.7. MS (EI, 70 eV)  $m/z$  (%): 447 (M<sup>+</sup> + 1, 19), 366 (98), 327 (20), 298 (1), 273 (19), 247 (31), 215 (19), 183 (8), 157 (17), 115 (44), 93 (100), 65 (18). Anal. Calcd. for  $C_{25}H_{20}BrNO_2$ : C, 67.27; H, 4.52; N, 3.14. Found: C, 67.40; H, 4.64; N, 3.22.

# *6-(3-nitrophenyl)-2-oxo-N,4-diphenylcyclohex-3 enecarboxamide (4b)*

Pale yellow solid, yield: (98%); mp 200–202 ◦C. IR (KBr)  $(v_{\text{max}}/\text{cm}^{-1})$ : 3413, 1632, 1601, 1558, 1531, 1445, 1353, 758, 689. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 3.08 (dd,  $J =$ 18.0, 8.4 Hz, 1H, H-5), 3.38 (dd, *J* = 18.2, 4.8 Hz, 1H, H − 5), 3.76 (d, *J* = 8.8 Hz, 1H, H-1), 4.32 (dd, *J* = 13.1, 8.8 Hz, 1H, H-6), 6.63 (s, 1H, H-3), 7.10 (t, *J* = 7.6 Hz, 1H, Ar-H), 7.28 (dd, *J* = 9.2, 5.2 Hz, 2H, Ar-H), 7.45 (d, *J* = 2.4 Hz, 2H, Ar-H), 7.48 (d, *J* = 7.2 Hz, 3H, Ar-H), 7.52 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.57 (t, *J* = 6.4 Hz, 2H, Ar-H), 7.69 (d, *J* = 7.6 Hz, 1H, Ar-H), 8.13 (d, *J* = 8.4 Hz,

1H, Ar-H), 8.19 (s, 1H, Ar-H), 8.25 (s, 1H, NH). 13C NMR (100 MHz, CDCl3): δ 33.8, 41.0, 58.5, 120.0, 122.0, 122.3, 124.4, 124.6, 126.3, 128.9, 129.0, 129.8, 131.0, 134.2, 137.3, 137.3 148.5, 159.6, 164.4, 194.5. MS (EI, 70 eV) *m*/*z* (%): 412 ( $M^+$ , 29), 369 (1), 344 (1), 320 (9), 293 (87), 270 (1), 246 (16), 224 (1), 202 (30), 176 (39), 144 (27), 115 (69), 93 (100), 65 (24). Anal. Calcd. for  $C_{25}H_{20}N_2O_4$ : C, 72.80; H, 4.89; N, 6.79. Found: C, 72.86; H, 4.96; N, 6.85.

# *6-(2-chlorophenyl)-2-oxo-N,4-diphenylcyclohex-3 enecarboxamide (4c)*

White solid, yield: (97%); mp 224–226 ◦C. IR (KBr)  $(v_{\text{max}}/cm^{-1})$ : 3383, 3084, 1674, 1627, 1601, 1559, 1445, 1249, 1180, 757, 693. 1H NMR (400 MHz, DMSO): 3.03 (d, *J* = 7.2 Hz, 2H, H-5), 4.24 (d, *J* = 13.2 Hz, 1H, H-1), 4.30 (dd, *J* = 14.0, 7.2 Hz, 1H, H-6), 6.63 (s, 1H, H-3), 7.00 (t, *J* = 7.6 Hz, 1H, Ar-H), 7.24 (t, *J* = 7.6 Hz, 3H, Ar-H), 7.35 (t, *J* = 7.2 Hz, 1H, Ar-H), 7.46 (dd, *J* = 15.2, 9.2 Hz, 6H, Ar-H), 7.67 (d, *J* = 7.6 Hz, 1H, Ar-H), 7.72 (d,  $J = 7.6$  Hz, 2H, Ar-H), 10.26 (s, 1H, NH). <sup>13</sup>C NMR (100 MHz, DMSO): δ 34.6, 39.6, 58.6, 119.4, 123.7, 124.0, 126.8, 127.0, 127.9, 128.4, 128.9, 129.1, 129.3, 130.1, 131.0, 133.4, 137.6, 139.2, 139.6, 158.7, 167.4, 195.7. MS (EI, 70 eV) *m*/*z* (%): 401 (M+, 3), 347 (2), 283 (3), 265 (4), 236 (3), 219 (5), 197 (3), 179 (5), 160 (4), 132 (5), 108 (48), 81 (28), 52 (100). Anal. Calcd. for C<sub>25</sub>H<sub>20</sub>ClNO<sub>2</sub>: C, 74.71; H, 5.02; N, 3.49. Found: C, 74.75; H, 5.06; N, 3.55.

## *6-(4-methoxyphenyl)-2-oxo-N,4-diphenylcyclohex-3 enecarboxamide (4d)*

White solid, yield: (96%); mp 217–219 ◦C. IR (KBr)  $(v_{\text{max}}/\text{cm}^{-1})$ : 3306, 3203, 1680, 1666, 1651, 1603, 1547, 1444, 1362, 1175, 759, 692. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 2.32 (s, 3H, OCH3), 3.06 (dd, *J* = 18.4, 7.6 Hz, 1H, H-5), 3.36 (dd,  $J = 18.4$ , 4.8 Hz, 1H, H'  $-$  5), 3.71 (d,  $J = 8.0$  Hz, 1H, H-1), 4.17 (dd,  $J = 12.8$ , 7.6 Hz, 1H, H-6), 6.58 (s, 1H, H-3), 7.08 (t, *J* = 7.2 Hz, 1H, Ar-H), 7.12  $(d, J = 8.0 \text{ Hz}, 2H, Ar-H), 7.21 (d, J = 8.0 \text{ Hz}, 2H, Ar-H),$ 7.28 (t, *J* = 8.4 Hz, 3H, Ar-H), 7.40–7.47 (m, 5H, Ar-H), 7.56 (t, *<sup>J</sup>* <sup>=</sup> <sup>6</sup>.4 Hz, 2H, Ar-H), 8.01 (s, 1H, NH). 13C NMR (100 MHz, CDCl3): δ 21.0, 34.1, 40.9, 59.5, 124.2, 124.3, 126.3, 126.4, 127.2, 128.8, 128.9, 129.4, 129.4, 130.6, 136.7, 137.6, 137.8 139.2, 160.0, 165.4, 195.8; MS (EI, 70 eV) *m*/*z*  $(\%):$  397  $(M^+, 1)$ , 392  $(1)$ , 381  $(35)$ , 344  $(1)$ , 289  $(4)$ , 261 (100), 228 (6), 202 (3), 171 (4), 145 (25), 115 (23), 93 (37), 65 (6). Anal. Calcd. for C25H20N2O4: C, 78.57; H, 5.83; N, 3.52. Found: C, 78.70; H, 5.94; N, 3.60.

# *6-(4-nitrophenyl)-2-oxo-N,4-diphenylcyclohex-3 enecarboxamide (4e)*

Pale yellow solid, yield:  $(94\%)$ ; mp 202–204 °C. IR (KBr)  $(v_{\text{max}}/cm^{-1})$ : 3415, 3304, 1663, 1606, 1555, 1517, 1445, 1349, 1176, 854, 759, 752, 692. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 3.05 (dd,  $J = 18.0$ , 8.4 Hz, 1H, H-5), 3.33 (dd,  $J = 18.0$ , 4.8 Hz, 1H,  $H'$  – 5), 3.76 (d,  $J = 9.2$  Hz, 1H, H-1), 4.27 (m, 1H, H-6), 6.58 (s, 1H, H-3), 7.09 (t, *J*= 7.2 Hz, 1H, Ar-H), 7.27 (t, *J* = 8.0 Hz, 2H, Ar-H), 7.39–7.48 (m, 5H, Ar-H), 7.49–7.55 (m, 4H, Ar-H), 8.16 (d, *J* = 8.4 Hz, 2H, Ar-H), 8.32 (s, 1H, NH). 13C NMR (100 MHz, CDCl3): δ 33.8, 41.3, 58.4, 120.0, 124.0, 124.2, 124.7, 126.3, 126.3, 128.4, 128.7, 128.9, 129.0, 131.0, 137.2, 137.3 146.9, 149.8, 159.5, 164.7, 194.7. MS (EI, 70 eV) *m*/*z*(%): 412 (M+, 44), 344 (7), 320 (7), 292 (82), 266 (14), 228 (4), 202 (12), 157 (30), 115 (27), 93 (100), 66 (19). Anal. Calcd. for C<sub>25</sub>H<sub>20</sub>N<sub>2</sub>O<sub>4</sub>: C, 72.80; H, 4.89; N, 6.79. Found: C, 72.87; H, 4.94; N, 6.85.

# *6-(2,6-dichlorophenyl)-2-oxo-N,4-diphenylcyclohex-3 enecarboxamide (4f)*

White solid, yield: (95%); mp 188–190 ◦C. IR (KBr)  $(v_{\text{max}}/\text{cm}^{-1})$ : 3418, 3387, 1698, 1659, 1600, 1517, 1436, 1360, 1172, 768, 757, 691. 1H NMR (400MHz, CDCl3): 2.98  $(\text{dd}, J = 18.0, 4.8 \text{ Hz}, 1H, H-5), 3.60 \text{ (ddd}, J = 18.8, 12.0,$ 2.4 Hz, 1H, H' – 5), 4.78 (d,  $J = 13.2$  Hz, 1H, H-1), 5.01 (td,  $J = 12.4, 4.8$  Hz, 1H, H-6), 6.64 (d,  $J = 2.4$  Hz, 1H, H-3), 7.05 (t, *J* = 7.2 Hz, 1H, Ar-H), 7.15 (t, *J* = 8.0 Hz, 1H, Ar-H), 7.25 (t, *J* = 8.0 Hz, 2H, Ar-H), 7.30 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.41 (dd, *J* = 8.0, 1.2 Hz, 1H, Ar-H), 7.44 (d, *J* = 3.2 Hz, 2H, Ar-H), 7.46–7.49 (m, 3H, Ar-H), 7.59– 7.61 (m, 2H, Ar-H), 8.21 (s, 1H, NH). 13C NMR (100 MHz, CDCl3): δ 30.4, 38.7, 55.6, 120.1, 124.2, 126.2, 128.8, 128.9, 129.3, 130.2, 130.7, 133.9, 135.9, 137.1, 137.5 137.6, 159.6, 165.5, 195.1. MS (EI, 70 eV) *m*/*z* (%): 436 (M+, 6), 435 (14), 400 (100), 372 (1), 343 (6), 316 (36), 281 (36), 256 (9), 226 (6), 199 (32), 157 (35), 115 (45), 93 (71), 65 (20). Anal. Calcd. for C<sub>25</sub>H<sub>19</sub>Cl<sub>2</sub>NO<sub>2</sub>: C, 68.82; H, 4.39; N, 3.21. Found: C, 68.88; H, 3.30; N, 6.85.

# *6-(4-cyanophenyl)-2-oxo-N,4-diphenylcyclohex-3 enecarboxamide (4g)*

White solid, yield: (99%); mp 224–226 ◦C. IR (KBr)  $(v_{\text{max}}/cm^{-1})$ : 3308, 2230, 1672, 1656, 1603, 1543, 1443, 757, 692. <sup>1</sup>H NMR (400 MHz, DMSO): 3.07 (dd,  $J = 18.0$ , 4.0 Hz, 1H, H-5), 3.18 (dd,  $J = 17.6$ , 10.4 Hz, 1H, H'  $- 5$ ), 3.95 (td, *J* = 13.2, 4.8 Hz, 1H, H-6), 4.02 (d, *J* = 13.2 Hz, 1H, H-1),  $6.60$  (d,  $J = 1.6$  Hz, 1H, H-3), 7.01 (t,  $J = 7.2$  Hz, 1H, Ar-H), 7.24 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.44 (d,  $J = 8.8$  Hz, 3H, Ar-H), 7.47 (d,  $J = 0.8$  Hz, 2H, Ar-H), 7.66 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.73 (t, *J* = 5.2 Hz,

2H, Ar-H), 7.80 (d, *J* = 8.0 Hz, 2H, Ar-H), 10.10 (s, 1H, NH). 13C NMR (100 MHz, DMSO): δ 35.1, 43.4, 59.3, 110.2, 119.2, 119.5, 123.8, 123.9, 126.9, 129.1, 129.2, 129.3, 131.0, 132.8, 137.7 139.0, 148.3, 159.2, 167.4, 195.3. MS (EI, 70 eV)  $m/z(\%)$ : 392 (M<sup>+</sup>, 41), 344 (5), 300 (7), 272 (100), 243 (6), 196 (4), 157 (38), 115 (35), 93 (70), 65 (14). Anal. Calcd. for  $C_{26}H_{20}N_2O_2$ : C, 79.57; H, 5.14; N, 7.14. Found: C, 79.70; H, 5.22; N, 7.21.

# *6-(3-chlorophenyl)-2-oxo-N,4-diphenylcyclohex-3 enecarboxamide (4h)*

White solid, yield: (95%); mp 187–189 ◦C. IR (KBr)  $(v_{\text{max}}/cm^{-1})$ : 3368, 3302, 3086, 1665, 1628, 1600, 1560, 1498, 1445, 1368, 1247, 758, 692. <sup>1</sup>H NMR (400 MHz, DMSO): 3.06 (dd, *J* = 18.0, 4.4 Hz, 1H, H-5), 3.17 (m, 1H,  $H'$  – 5), 3.86 (td,  $J = 12.8$ , 4.4 Hz, 1H, H-6), 3.97 (d, *J* = 13.2 Hz, 1H, H-1), 6.58 (d, *J* = 2.0 Hz, 1H, H-3), 7.01 (t, *J*= 7.2 Hz, 1H, Ar-H), 7.24 (d, *J* = 8.4 Hz, 2H, Ar-H), 7.27 (t, *J* = 2.0 Hz, 1H, Ar-H), 7.34 (t, *J*= 8.0 Hz, 1H, Ar-H), 7.40 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.44–7.47 (m, 5H, Ar-H), 7.55 (s, 1H, Ar-H), 7.74 (dd, *J* = 7.2, 2.4 Hz, 2H, Ar-H), 10.08 (s, 1H, NH). <sup>13</sup>C NMR (100 MHz, DMSO):  $\delta$  35.5, 43.1, 59.7, 119.6, 123.8, 126.8, 126.9, 127.3, 128.0, 129.1, 129.3, 130.6, 130.9, 133.4, 137.8, 139.1, 145.1, 159.4, 167.6, 195.5. MS (EI, 70 eV) *m*/*z* (%): 401 (M+, 39), 342 (3), 309 (7), 281 (90), 252 (5), 228 (13), 202 (13), 179 (1), 157 (34), 115 (45), 93 (100), 65 (20). Anal. Calcd. for  $C_2$ <sub>5</sub>H<sub>20</sub>ClNO<sub>2</sub>: C, 74.71; H, 5.02; N, 3.49. Found: C, 74.78; H, 5.15; N, 3.62.

# *2-oxo-N,4-diphenyl-6-(pyridin-3-yl)cyclohex-3 enecarboxamide (4i)*

White solid, yield: (92%); mp 195–197 ◦C. IR (KBr)  $(v_{\text{max}}/\text{cm}^{-1})$ : 3399, 3086, 1696, 1633, 1607, 1557, 1444, 1369, 1235, 1176, 756, 715, 693. 1H NMR (400 MHz, DMSO): 3.09 (dd, *J* = 18.2, 4.4 Hz, 1H, H-5), 3.21 (ddd,  $J = 18.0, 11.4, 2.0$  Hz, 1H,  $H' - 5$ ), 3.88 (td,  $J = 13.0$ , 4.8 Hz, 1H, H-6), 3.51 (d, *J* = 12.8 Hz, 1H, H-1), 6.60 (d, *J* = 2.0 Hz, 1H, H-3), 7.01 (t, *J* = 7.2 Hz, 1H, Ar-H), 7.24 (t, *J* = 12.8 Hz, 2H, Ar-H), 7.35 (dd, *J* = 4.8, 7.6 Hz, 1H, Ar-H), 7.43 (d, *J* = 7.6 Hz, 2H, Ar-H), 7.47 (dd, *J* = 2.4, 5.2 Hz, 2H, Ar-H), 7.75 (dd, *J* = 7.4, 2.4 Hz, 2H, Ar-H), 7.89 (d, *J* = 8.0 Hz, 1H, Ar-H), 8.42 (dd, *J* = 4.8, 1.2 Hz, 1H, Ar-H), 8.65 (d, *J*= 1.6 Hz, 1H, Ar-H), 10.10 (s, 1H, NH). 13C NMR (100 MHz, DMSO): δ 35.2, 41.1, 59.6, 119.5, 123.9, 126.9, 129.1, 129.3, 130.9, 135.5, 137.8, 137.9, 139.0, 148.6, 149.7, 159.4, 167.5, 195.4. MS (EI, 70 eV) *m*/*z* (%): 368 (M+, 43), 344 (1), 309 (2), 281 (39), 248 (100), 220 (14), 197 (3), 157 (21), 132 (28), 93 (96), 65 (13). Anal. Calcd. for C<sub>24</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub>: C, 78.24; H, 5.47; N, 7.60. Found: C, 78.31; H, 5.58; N, 7.69.

# *2-oxo-N,4-diphenyl-6-(pyridin-4-yl)cyclohex-3 enecarboxamide (4j)*

White solid, yield: (97%); mp 202–204 ◦C. IR (KBr)  $(v_{\text{max}}/\text{cm}^{-1})$ : 3467, 3267, 3073, 1695, 1647, 1603, 1555, 1497, 1444, 1366, 1177, 756, 692. 1H NMR (400 MHz, DMSO): 3.08 (dd, *J* = 18.0, 4.8 Hz, 1H, H-5), 3.17 (dd,  $J = 17.6, 11.4, Hz, 1H, H' - 5$ , 3.87 (td,  $J = 13.2, 4.8$ Hz, 1H, H-6), 4.01 (d, *J* = 13.2 Hz, 1H, H-1), 6.60 (d, *J* = 1.6 Hz, 1H, H-3), 7.01 (t, *J* = 7.2 Hz, 1H, Ar-H), 7.25 (t, *J* = 8.0 Hz, 2H, Ar-H), 7.45 (t, *J* = 7.6 Hz, 7H, Ar-H), 7.74 (t, *J* = 5.6 Hz, 2H, Ar-H), 8.51 (d, *J* = 6.0 Hz, 2H, Ar-H), 10.13 (s, 1H, NH). 13C NMR (100 MHz, DMSO): δ 34.8, 42.7, 59.0, 119.5, 123.4, 123.8, 123.9, 126.9, 129.1, 129.3, 131.0, 137.7, 139.0, 150.1, 151.3, 159.2, 167.4, 195.2. MS (EI, 70 eV) *m*/*z* (%): 368 (M+, 30), 344 (1), 309 (2), 281 (29), 248 (19), 220 (10), 197 (3), 171 (15), 144 (34), 115 (55), 93 (100), 65 (25). Anal. Calcd. for  $C_{24}H_{20}N_2O_2$ : C, 78.24; H, 5.47; N, 7.60. Found: C, 78.31; H, 5.58; N, 7.69.

## *6-(2,3-dimethoxyphenyl)-2-oxo-N,4-diphenylcyclohex-3 enecarboxamide (4k)*

White solid, yield: (90%); mp 196–198 °C. IR (KBr)  $(v_{\text{max}}/\text{cm}^{-1})$ : 3413, 1666, 1600, 1556, 1477, 1445, 1365, 1274, 1073, 1002, 756, 693. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 3.01 (d, *J* = 17.6 Hz, 1H, H-5), 3.44 (ddd, *J* = 17.5, 10.0,  $3.2$  Hz,  $1H, H' - 5$ ),  $3.88$  (s,  $3H, OCH_3$ ),  $4.06$  (s,  $3H, OCH_3$ ), 4.49 (d,  $J = 8.8$  Hz, 2H, H-1 and H-6), 6.53 (d,  $J = 2.8$  Hz, 1H, H-3), 6.79 (dd, *J* = 8.0, 1.2 Hz, 1H, Ar-H), 6.96 (t,  $J = 8.0$  Hz, 1H, Ar-H), 7.08 (t,  $J = 7.2$  Hz, 1H, Ar-H), 7.22 (dd,  $J = 8.0$ , 1.2 Hz, 1H, Ar-H), 7.32 (t,  $J = 8.4$  Hz, 3H, Ar-H), 7.39 (d, *J* = 7.2 Hz, 2H, Ar-H), 7.51-7.55 (m, 4H, Ar-H), 8.24 (s, 1H, NH). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 28.6, 36.0, 55.6, 58.2, 60.8, 111.3, 119.8, 120.3, 121.6, 123.9, 124.8, 125.1, 126.4, 127.7, 128.9, 130.5, 135.7, 137.7, 146.7, 152.9, 160.1, 165.5, 196.0. MS (EI, 70 eV) *m*/*z* (%): 354 (M<sup>+</sup> −1, 2), 368 (3), 344 (1), 299 (7), 265 (1), 241 (100), 198 (26), 172 (1), 150 (74), 115 (15), 91 (7), 57 (9). Anal. Calcd. for  $C_{27}H_{25}NO_4$ : C, 75.86; H, 5.89; N, 3.28. Found: C, 75.95; H, 5.94; N, 3.40.

**Acknowledgments** Financial support from the Research Council of the University of Sistan and Baluchestan is gratefully acknowledged.

#### <span id="page-6-0"></span>**References**

- 1. Awasthi SK, Mishra N, Kumar B, Sharma M, Bhattacharya A, Mishra LC, Bhasin VK (2009) Potent antimalarial activity of newly synthesized substituted chalcone analogs in vitro. Med Chem Res 18:407–420. doi[:10.3390/molecules170910331](http://dx.doi.org/10.3390/molecules170910331)
- <span id="page-6-11"></span>2. Lim SS, Kim HS, Lee DU (2007) In vitro antimalarial activity of flavonoids and chalcones. Bull Korean Chem Soc 28:2495–2497
- <span id="page-6-19"></span>3. Rahman MA (2011) Chalcone: a valuable insight into the recent advances and potential pharmacological activities. Chem Sci J 2011:1–16. doi[:10.4172/2150-3494.1000021](http://dx.doi.org/10.4172/2150-3494.1000021)
- <span id="page-6-1"></span>4. Saini RK, Choudhary AS, Joshi YC, Joshi P (2005) Solvent free synthesis of chalcones and their antibacterial activities. E-J Chem 2:224–227. doi[:10.1155/2005/294094](http://dx.doi.org/10.1155/2005/294094)
- <span id="page-6-2"></span>5. Hussain MA (2001) Synthesis of aurentiacin. Indian J Chem 40B:324–326
- 6. Baradia R, Rao JT (2004) Synthesis and antimicrobial activity of some  $\alpha$ ,  $\beta$ -unsaturated aromatic ketones. Asian J Chem 16:1194– 1196
- <span id="page-6-3"></span>7. Ilango K, Valentina P, Saluja G (2010) Synthesis and in vitro anticancer activity of some substituted chalcones derivatives. Res J Pharm Biol Chem Sci 1:354–359
- <span id="page-6-4"></span>8. Zhang XW, Zhao DH, Quan YC, Sun LP, Yin XM, Guan LP (2010) Synthesis and evaluation of anti-inflammatory activity of substituted chalcone derivatives. Med Chem Res 19:403–412. doi[:10.](http://dx.doi.org/10.1007/s00044-009-9202-z) [1007/s00044-009-9202-z](http://dx.doi.org/10.1007/s00044-009-9202-z)
- <span id="page-6-5"></span>9. Bhatia NM, Mahadik KR, Bhatia MS (2009) QSAR analysis of 1,3-diaryl-2-propen-1-ones and their indole analogs for designing potent antibacterial agents. Chem Pap 63:456–463
- <span id="page-6-6"></span>10. Kaushik S, Kumar N, Drabu S (2010) Synthesis and anticonvulsant activities of phenoxychalcones. T Ph Res 3:257–262
- <span id="page-6-7"></span>11. Romagnoli R, Baraldi PG, Carrion MD, Cara CL, Cruz-Lopez O, Preti D (2008) Design, synthesis, and biological evaluation of thiophene analogues of chalcones. Bioorg Med Chem 16:5367–5376. doi[:10.1016/j.bmc.2008.04.026](http://dx.doi.org/10.1016/j.bmc.2008.04.026)
- <span id="page-6-8"></span>12. Lahtchev KL, Batovska DI, Parushev SP, Ubiyvovk VM, Sibirny AA (2008) Antifungal activity of chalcones: a mechanistic study using various yeast strains. Eur J Med Chem 43:2220–2228. doi[:10.](http://dx.doi.org/10.1016/j.ejmech.2007.12.027) [1016/j.ejmech.2007.12.027](http://dx.doi.org/10.1016/j.ejmech.2007.12.027)
- <span id="page-6-9"></span>13. Bag S, Ramar S, Degani MS (2009) Synthesis and biological evaluation of  $\alpha$ ,  $\beta$ -unsaturated ketone as potential antifungal agents. Med Chem Res 18:309–316. doi[:10.1007/s00044-008-9128-x](http://dx.doi.org/10.1007/s00044-008-9128-x)
- <span id="page-6-10"></span>14. Lunardi F, Guzela M, Rodrigues AT, Corre R, Eger-Mangrich I, Steindel M, Grisard EC, Assreuy J, Calixto JB, Santos ARS (2003) Trypanocidal and leishmanicidal properties of substitutioncontaining chalcones. Antimicrob Agents Chemother 47:1449– 1451. doi[:10.1128/AAC.47.4.1449-1451.2003](http://dx.doi.org/10.1128/AAC.47.4.1449-1451.2003)
- <span id="page-6-12"></span>15. Cheng MS, Shi R, Kenyon G (2000) A solid phase synthesis of chalcones by Claisen-Schmidt condensations. Chin Chem Lett 11:851– 854
- <span id="page-6-13"></span>16. Begum NA, Roy N, Laskar RA, Roy K (2010) Mosquito larvicidal studies of some chalcone analogues and their derived products: structure-activity relationship analysis. Med Chem Res 19: 1–14
- <span id="page-6-14"></span>17. Awasthi SK, Mishra N, Dixit SK, Singh A, Yadav M, Yadav SS, Rathaur S (2009) Antifilarial activity of 1,3-diarylpropen-1 one: effect on glutathione-S-transferase, a phase II detoxification enzyme. Am J Trop Med Hyg 80:764–768
- <span id="page-6-15"></span>18. Hamdi N, Fischmeister C, Puerta MC, Valerga P (2010) A rapid access to new coumarinyl chalcone and substituted chromeno[4,3 c]pyrazol-4(1H)-ones and their antibacterial and DPPH radical scavenging activities. Med Chem Res 19:1–16. doi[:10.2478/](http://dx.doi.org/10.2478/s11696-009-0026-6) [s11696-009-0026-6](http://dx.doi.org/10.2478/s11696-009-0026-6)
- <span id="page-6-16"></span>19. Vogel S, Ohmayer S, Brunner G, Heilmann J (2008) Natural and non-natural prenylated chalcones: synthesis, cytotoxicity and antioxidative activity. Bioorg Med Chem 16:4286–4293. doi[:10.1016/](http://dx.doi.org/10.1016/j.bmc.2008.02.079) [j.bmc.2008.02.079](http://dx.doi.org/10.1016/j.bmc.2008.02.079)
- <span id="page-6-17"></span>20. Sivakumar PM, Prabhakar PK, Doble M (2010) Synthesis, antioxidant evaluation and quantitative structure-activity relationship studies of chalcones. Med Chem Res 19:1–17. doi[:10.1007/](http://dx.doi.org/10.1007/s00044-010-9342-1) [s00044-010-9342-1](http://dx.doi.org/10.1007/s00044-010-9342-1)
- <span id="page-6-18"></span>21. Yayli N, Ucuncu O, Yasar A, Kucuk M, Akyuz E, Karaoglu SA (2006) Synthesis and biological activities of N-alkyl derivatives of o-, m-, and p-nitro (E)-4-azachalcones and stereoselective photo-

chemistry in solution with theoretical calculations. Turk J Chem 30:505–514

- <span id="page-7-0"></span>22. Najafian M, Ebrahim-Habibi A, Hezareh N, Yaghmaei P, Parivar K, Larijani B (2010) Trans-chalcone: a novel small molecule inhibitor of mammalian alpha-amylase. Mol Biol Rep 10:271–274. doi[:10.](http://dx.doi.org/10.1007/s11033-010-0271-3) [1007/s11033-010-0271-3](http://dx.doi.org/10.1007/s11033-010-0271-3)
- <span id="page-7-1"></span>23. Chimenti F, Fioravanti R, Bolasco A, Chimenti P, Secci D, Rossi F, Yanez M, Francisco OF, Ortuso F, Alcaro S (2009) Chalcones: a valid scaffold for monoamine oxidases inhibitors. J Med Chem 10:1–8. doi[:10.1021/jm801590u](http://dx.doi.org/10.1021/jm801590u)
- <span id="page-7-2"></span>24. Zarghi A, Zebardast T, Hakimion F, Shirazi FH, Rao PNP, Knaus EE (2006) Synthesis and biological evaluation of 1,3 diphenylprop-2-en-1-ones possessing a methanesulfonamido or an azido pharmacophore as cyclooxygenase-1/-2 inhibitors. Bioorg Med Chem 14:7044–7050. doi[:10.1016/j.bmc.2006.06.022](http://dx.doi.org/10.1016/j.bmc.2006.06.022)
- <span id="page-7-3"></span>25. Sibi MP, Manyem S (2000) Enantioselective conjugate additions. Tetrahedron 56:8033–8061. doi[:10.1016/S0040-4020\(00\)00618-9](http://dx.doi.org/10.1016/S0040-4020(00)00618-9)
- 26. Berner OE, Tedeschi L, Enders D (2002) Asymmetric Michael additions to nitroalkenes. Eur J Org Chem 2002:1877–1894. doi[:10.1002/1099-0690\(200206\)2002:12<1877::aid-ejoc1877>3.](http://dx.doi.org/10.1002/1099-0690(200206)2002:12<1877::aid-ejoc1877>3.0.co;2-u) [0.co;2-u](http://dx.doi.org/10.1002/1099-0690(200206)2002:12<1877::aid-ejoc1877>3.0.co;2-u)
- <span id="page-7-4"></span>27. Dalko PI, Moisan L (2004) In the golden age of organocatalysis. Angew Chem Int Ed 43:5138–5175. doi[:10.1002/anie.200400650](http://dx.doi.org/10.1002/anie.200400650)
- <span id="page-7-5"></span>28. House HO (1972) Modern synthetic reactions, 2nd ed. Benjamin WA, Menlo Park, p 595
- <span id="page-7-6"></span>29. Jung ME (1991) In: Trostand BM, Fleming I (eds) Comprehensive organic synthesis. Pergamon Press, Oxford, p 1
- <span id="page-7-7"></span>30. Padmavathi V, Sharmila K, Reddy AS, Reddy DB (2001) Reactivity of 3,5-diaryl cyclohexanones—synthesis of spiro cyclohexanes. Indian J Chem 40B:11–14
- <span id="page-7-8"></span>31. Padmavathi V, Sharmila K, Balaiah A, Reddy AS, Reddy DB (2001) Cyclohexenone carboxylates. A versatile source for fused isoxazoles and pyrazoles. Synth Commun 31:2119–2126. doi[:10.](http://dx.doi.org/10.1081/SCC-100104462) [1081/SCC-100104462](http://dx.doi.org/10.1081/SCC-100104462)
- <span id="page-7-9"></span>32. Reddy DB, Reddy AS, Padmavathi V (1998) Synthesis of annelated 1,2,3-selena- or -thia-diazoles. J Chem Res 784–785. doi[:10.1039/](http://dx.doi.org/10.1039/A804381G) [A804381G](http://dx.doi.org/10.1039/A804381G)
- <span id="page-7-10"></span>33. Gopalakrishnan M, Thanusu J, Kanagarajan V (2008) Synthesis and characterization of 4,6-diaryl-4,5-dihydro-2H-indazol-3 ols and 4,6-diaryl-2-phenyl-4,5-dihydro-2H-indazol-3-ols - a new series of fused indazole derivatives. Chem Hetero Comp 44:950– 955. doi[:10.1007/s10593-008-0137-y](http://dx.doi.org/10.1007/s10593-008-0137-y)
- <span id="page-7-11"></span>34. Padmavathi V, Sharmila K, Padmaja A, Reddy DB (1999) An efficient synthesis of 6,8-diarylcarbazoles via Fischer indole cyclizations. Heterocycl Commun 5:451–456. doi[:10.1515/HC.1999.5.5.](http://dx.doi.org/10.1515/HC.1999.5.5.451) [451](http://dx.doi.org/10.1515/HC.1999.5.5.451)
- <span id="page-7-12"></span>35. Hoye TR, Tennakoon MA (2000) Synthesis (and alternative proof of configuration) of the scyphostatin  $C(1')$ - $C(20')$  trienoyl fragment. Org Lett 2:1481–1483. doi[:10.1021/ol0058386](http://dx.doi.org/10.1021/ol0058386)
- <span id="page-7-13"></span>36. Hiromichi F, Naoyuki K, Yoshinari S, Yasushi N, Yasuyuki K (2002) Concise asymmetric synthesis of a model compound, (4*S*,5*S*,6*S*)-6-(2,2-dimethoxy)ethyl-4,5-epoxy-6-hydroxy-2 cyclohexenone, for the cyclohexenone core of scyphostatin. Tetrahedron Lett 43:4825–4828. doi[:10.1016/s0040-4039\(02\)00916-4](http://dx.doi.org/10.1016/s0040-4039(02)00916-4)
- <span id="page-7-14"></span>37. Safaei-Ghomi J, Alishahi Z (2005) The preparation of some novel indazole derivatives by using chalcones. J Fudan Univ Nat Sci 44(5):789–790
- <span id="page-7-15"></span>38. Mc Bride C, Renhowe P, Heise C, Jansen J, Lapointe G, Ma S, Pineda R, Vora J, Wiesmann M, Shafer C (2006) Design and structure-activity relationship of 3−benzimidazol−2−yl−1Hindazoles as inhibitors of receptor tyrosine kinases. Bioorg Med Chem Lett 16:3595–3599. doi[:10.1016/j.bmcl.2006.03.069](http://dx.doi.org/10.1016/j.bmcl.2006.03.069)
- <span id="page-7-16"></span>39. Kim BC, Kim JL, Jhang YU (1994) Bull Korean Chem Soc 15(2): 97. Chem. Abstr 121:50097z
- <span id="page-7-17"></span>40. Yamaguchi M, Maruyama N, Koga T, Kamei K, Akima M, Kuroki T, Hamana M, Ohi N (1995) Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation, VI: Indazole derivatives. Chem Pharm Bull 43(2):332–334
- <span id="page-7-18"></span>41. Gorge V, De L, Kim UT, Jing L (1998) Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues. J Med Chem 41(13):2411–2423. doi[:10.1021/](http://dx.doi.org/10.1021/jm980103g) im980103g
- <span id="page-7-19"></span>42. Vyas DH, Tala SD, Akbari JD, Dhaduk MF, Joshi HS (2009) Synthesis, antimicrobial and antitubercular activity of some cyclohexenone and indazole derivatives. Indian J Chem 48B:1405–1410
- <span id="page-7-20"></span>43. Abdel-Rahman AAH, Abdel-Megied AES, Hawata MAM, Kasem ER, Shabaan MT (2007) Synthesis and antimicrobial evaluation of some chalcones and their derived pyrazoles, pyrazolines, isoxazolines, and 5,6-dihydropyrimidine-2-(1H)-thiones. Monatshefte Chem 138:889–897. doi[:10.1007/s00706-007-0700-8](http://dx.doi.org/10.1007/s00706-007-0700-8)
- 44. Ducki S, Forrest R, Hadfield JA, Kendall A, Lawrence NJ, McGown AT, Rennisonl D (1998) Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorg Med Chem Lett 8:1051–1056. doi[:10.1016/S0960-894X\(98\)00162-0](http://dx.doi.org/10.1016/S0960-894X(98)00162-0)
- <span id="page-7-21"></span>45. Bhat BA, Dhar KL, Puri SC, Saxena AK, Shanmugavel M, Qazi GN (2005) Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents. Bioorg Med Chem Lett 15:3177–3180. doi[:10.1016/j.bmcl.2005.03.121](http://dx.doi.org/10.1016/j.bmcl.2005.03.121)
- <span id="page-7-22"></span>46. Sobhani S, Nasseri R, Honarmand M (2012) 2- Hydroxyethylammonium acetate as a reusable and cost-effective ionic liquid for the efficient synthesis of bis(pyrazolyl)methanes and 2-pyrazolyl-1-nitroalkanes. Can J Chem 90:798–804. doi[:10.](http://dx.doi.org/10.1139/v2012-059) [1139/v2012-059](http://dx.doi.org/10.1139/v2012-059)
- <span id="page-7-23"></span>47. Yue C, Mao A, Wei Y, Lü M (2008) Knoevenagel condensation reaction catalyzed by task-specific ionic liquid under solvent-free conditions. Catal Commun 9:1571–1574. doi[:10.1016/j.catcom.](http://dx.doi.org/10.1016/j.catcom.2008.01.002) [2008.01.002](http://dx.doi.org/10.1016/j.catcom.2008.01.002)